Canandaigua National Corp Sells 210 Shares of Danaher Co. (NYSE:DHR)

Canandaigua National Corp lowered its stake in shares of Danaher Co. (NYSE:DHRGet Rating) by 1.5% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 14,055 shares of the conglomerate’s stock after selling 210 shares during the period. Canandaigua National Corp’s holdings in Danaher were worth $3,563,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Norges Bank purchased a new stake in Danaher during the fourth quarter valued at $2,015,889,000. Castleview Partners LLC purchased a new stake in shares of Danaher during the 4th quarter valued at about $4,077,000. AustralianSuper Pty Ltd lifted its stake in shares of Danaher by 916.7% in the 1st quarter. AustralianSuper Pty Ltd now owns 1,168,431 shares of the conglomerate’s stock worth $342,736,000 after purchasing an additional 1,053,502 shares during the period. Vanguard Group Inc. grew its position in Danaher by 2.1% during the first quarter. Vanguard Group Inc. now owns 51,004,840 shares of the conglomerate’s stock valued at $14,961,250,000 after buying an additional 1,044,650 shares during the period. Finally, Flossbach Von Storch AG increased its holdings in Danaher by 68.2% during the first quarter. Flossbach Von Storch AG now owns 2,453,197 shares of the conglomerate’s stock valued at $719,596,000 after buying an additional 994,835 shares during the last quarter. Hedge funds and other institutional investors own 77.27% of the company’s stock.

Danaher Price Performance

DHR stock opened at $277.06 on Monday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.75. The company’s fifty day moving average price is $279.57 and its 200-day moving average price is $269.82. Danaher Co. has a one year low of $233.71 and a one year high of $331.68. The company has a market capitalization of $201.55 billion, a PE ratio of 32.63, a price-to-earnings-growth ratio of 1.33 and a beta of 0.88.

Danaher (NYSE:DHRGet Rating) last released its quarterly earnings data on Thursday, July 21st. The conglomerate reported $2.76 EPS for the quarter, beating the consensus estimate of $2.35 by $0.41. Danaher had a net margin of 20.61% and a return on equity of 18.57%. The business had revenue of $7.75 billion during the quarter, compared to the consensus estimate of $7.29 billion. During the same quarter in the prior year, the firm earned $2.46 EPS. The business’s revenue was up 7.4% on a year-over-year basis. On average, equities analysts anticipate that Danaher Co. will post 10.4 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Stockholders of record on Friday, September 30th will be issued a dividend of $0.25 per share. The ex-dividend date is Thursday, September 29th. This represents a $1.00 annualized dividend and a dividend yield of 0.36%. Danaher’s dividend payout ratio (DPR) is 11.78%.

Analyst Ratings Changes

Several brokerages have recently weighed in on DHR. StockNews.com upgraded shares of Danaher from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 26th. Sanford C. Bernstein began coverage on Danaher in a research report on Tuesday, August 16th. They issued an “outperform” rating and a $340.00 price target for the company. Royal Bank of Canada lifted their price objective on Danaher from $317.00 to $318.00 and gave the company an “outperform” rating in a research report on Friday. Cowen cut their price objective on Danaher to $340.00 in a research note on Friday, July 22nd. Finally, KeyCorp decreased their target price on shares of Danaher from $345.00 to $325.00 and set an “overweight” rating on the stock in a research note on Friday, July 22nd. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Danaher currently has an average rating of “Buy” and an average price target of $321.45.

Insider Activity

In related news, CEO Rainer Blair sold 25,000 shares of the company’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $300.00, for a total transaction of $7,500,000.00. Following the sale, the chief executive officer now owns 79,739 shares of the company’s stock, valued at $23,921,700. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, EVP Joakim Weidemanis sold 12,000 shares of the firm’s stock in a transaction that occurred on Monday, July 25th. The stock was sold at an average price of $271.13, for a total value of $3,253,560.00. Following the completion of the sale, the executive vice president now directly owns 74,398 shares of the company’s stock, valued at approximately $20,171,529.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Rainer Blair sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $300.00, for a total value of $7,500,000.00. Following the transaction, the chief executive officer now directly owns 79,739 shares in the company, valued at approximately $23,921,700. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,906 shares of company stock worth $11,823,179. 11.20% of the stock is currently owned by insiders.

Danaher Company Profile

(Get Rating)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRGet Rating).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.